Search...
FDA's new rule requiring one pivotal study caused fluctuations in biotech stocks: Medpace and Iqvia dropped, Viking Therapeutics rose.
On Thursday, biotech stocks and research shares experienced different trajectories following reports indicating the FDA's imminent mandate of a single pivotal study. This development caused concerns for Medpace and Iqvia but resulted in gains for Viking Therapeutics. The potential policy change reflects a shift in regulatory requirements and could significantly impact the industry.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments